Advancements in the treatment of epilepsy

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 503-523

  Leeman, B A ^a   Cole, A J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticonvulsants; Epilepsy surgery; Neuroimaging; Seizures

Indexed keywords

ACETAZOLAMIDE; ALUMINUM MAGNESIUM HYDROXIDE; BRIVARACETAM; CARBAMAZEPINE; DIGOXIN; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HALOPERIDOL; HARKOSERIDE; LAMOTRIGINE; LEVONORGESTREL; LITHIUM; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RITIGABINE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADD ON THERAPY; ANHIDROSIS; APLASTIC ANEMIA; BEHAVIOR CHANGE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COLOR VISION DEFECT; COUGHING; DIAGNOSTIC IMAGING; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPERCHLOREMIA; HYPERTHERMIA; HYPONATREMIA; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MACULOPAPULAR RASH; MENTAL DISEASE; METABOLIC ACIDOSIS; MONOTHERAPY; NEPHROLITHIASIS; NEPHROTOXICITY; OBSTRUCTIVE JAUNDICE; OPEN ANGLE GLAUCOMA; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RETINA DISEASE; REVIEW; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; STEVENS JOHNSON SYNDROME; STUPOR; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD DEFECT; WEIGHT REDUCTION;

ANTICONVULSANTS; DIAGNOSTIC IMAGING; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS;

EID: 39649085578     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.071105.110848     Document Type: Review

References (103)

1. Centers for Disease Control. 2005. Prevalence of epilepsy and health-related quality of life and disability among adults with epilepsy - South Carolina, 2003 and 2004. MMWR Weekly 54:8080-82
2. Kobau R, DiIorio CA, Price PH, et al. 2004. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance System, 2002. Epilepsy Behav. 5:358-66
3. Strine TW, Kobau R, Chapman DP, et al. 2005. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 46:1133-39
4. Knake S, Triantafyllou C, Wald LL, et al. 2005. 3T phased array MRI improves the presurgical evaluation in focal epilepsies: a prospective study. Neurology 65:1026-31
5. Ogawa S, Lee TM, Kay AR, et al. 1990. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. USA 87:9868-72
6. Salek-Haddadi A, Friston KJ, Lemieux L, et al. 2003. Studying spontaneous EEG activity with fMRI. Brain Res. Brain Res. Rev. 43:110-33
7. Salek-Haddadi A, Merschhemke M, Lemieux L, et al. 2002. Simultaneous EEG-correlated ictal fMRI. Neuroimage 16:32-40
8. Knowlton RC, Shih J. 2004. Magnetoencephalography in epilepsy. Epilepsia 45 (Suppl. 4):61-71
9. Van Paesschen W, 2004. Ictal SPECT. Epilepsia 45(Suppl. 4):35-40
10. Brunbech L, Sabers A. 2002. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 62:593-604
11. Asconapé JJ. 2002. Some common issues in the use of antiepileptic drugs. Semin. Neurol. 22:27-39
12. Karceski S, Morrell MJ, Carpenter D. 2005. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 7(Suppl. 1):S1,64; quiz S65-67
13. French J, Smith M, Faught E, et al. 1999. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52:1540-45
14. French JA, Kanner AM, Bautista J, et al. 2004. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62:1252-60
15. French JA, Kanner AM, Bautista J, et al. 2004. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62:1261-73
16. French JA, Kugler AR, Robbins JL, et al. 2003. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60:1631-37
17. Beydoun A, Uthman BM, Kugler AR, et al. 2005. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64:475-80
18. Arroyo S, Anhut H, Kugler AR, et al. 2004. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45:20-27
19. Glauser TA, Nigro M, Sachdeo R, et al. 2000. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 54:2237-44
20. Kothare SV, Khurana DS, Mostofi N, et al. 2006. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr. Neurol. 35:235-39
21. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. 2000. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 54:2245-51
22. Sachdeo R, Beydoun A, Schachter S, et al. 2001. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 57:864-71
23. Barcs G, Walker EB, Elger CE, et al. 2000. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41:1597-607
24. Bill PA, Vigonius U, Pohlmann H, et al. 1997. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 27:195-204
25. Guerreiro MM, Vigonius U, Pohlmann H, et al. 1997. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 27:205-13
26. Christe W, Kramer G, Vigonius U, et al. 1997. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 26:451-60
27. Dam M, Ekberg R, Loyning Y, et al. 1989. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3:70-76
28. Schmidt D, Elger CE. 2004. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 5:627-35
29. Palmieri A. 2007. Oxcarbazepine-induced headache. Cephalalgia 27:91-93
30. Faught E, Ayala R, Montouris GG, et al. 2001. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57:1774-79
31. Schmidt D, Jacob R, Loiseau P, et al. 1993. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 15:67-73
32. Kothare SV, Kaleyias J, Mostofi N, et al. 2006. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr. Neurol. 34:351-54
33. Yanai S, Hanai T, Narazaki O. 1999. Treatment of infantile spasms with zonisamide. Brain Dev. 21:157-61
34. Kyllerman M, Ben-Menachem E. 1998. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 29:109-14
35. Shorvon SD, Lowenthal A, Janz D, et al. 2000. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41:1179-86
36. Cereghino JJ, Biton V, Abou-Khalil B, et al. 2000. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55:236-42
37. Glauser TA, Ayala R, Elterman RD, et al. 2006. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66:1654-60
38. Glauser TA, Pellock JM, Bebin EM, et al. 2002. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518-24
39. Ben-Menachem E, Falter U. 2000. Efficacy and tolerability of levetiracetam 3 000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41:1276-83
40. Specchio LM, Gambardella A, Giallonardo AT, et al. 2006. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res. 71:32-39
41. Labate A, Colosimo E, Gambardella A, et al. 2006. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 15:214-18
42. Patel NC, Landan IR, Levin J, et al. 2006. The use of levetiracetam in refractory status epilepticus. Seizure 15:137-41
43. Sachdeo RC, Leroy RF, Krauss GL, et al. 1997. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch. Neurol. 54:595-601
44. Uthman BM, Rowan AJ, Ahmann PA, et al. 1998. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch. Neurol. 55:56-62
45. Richens A, Chadwick DW, Duncan JS, et al. 1995. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. 21:37-42
46. Koepp MJ, Edwards M, Collins J, et al. 2005. Status epilepticus and tiagabine therapy revisited. Epilepsia 46:1625-32
47. Gilliam FG, Veloso F, Bomhof MA, et al. 2003. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60:196-202
48. Arroyo S, Dodson WE, Privitera MD, et al. 2005. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 112:214-22
49. Ben-Menachem E, Henriksen O, Dam M, et al. 1996. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37:539-43
50. Biton V, Montouris GD, Ritter F, et al. 1999. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 52:1330-37
51. Sachdeo RC, Glauser TA, Ritter F, et al. 1999. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 52:1882-87
52. Silberstein SD. 2002. Control of topiramate-induced paresthesias with supplemental potassium. Headache 42:85
53. Matsuo F, Bergen D, Faught E, et al. 1993. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 43:2284-91
54. Messenheimer J, Ramsay RE, Willmore LJ, et al. 1994. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35:113-21
55. Schapel GJ, Beran RG, Vajda FJ, et al. 1993. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J. Neurol. Neurosurg. Psychiatry 56:448-53
56. Duchowny M, Pellock JM, Graf WD, et al. 1999. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 53:1724-31
57. Biton V, Sackellares JC, Vuong A, et al. 2005. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65:1737-43
58. Motte J, Trevathan E, Arvidsson JF, et al. 1997. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N. Engl. J. Med. 337:1807-12
59. Gilliam F, Vazquez B, Sackellares JC, et al. 1998. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 51:1018-25
60. Steinhoff BJ, Ueberall MA, Siemes H, et al. 2005. The LAM-SAFE study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 14:597-605
61. Steiner TJ, Dellaportas CI, Findley LJ, et al. 1999. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40:601-7
62. Brodie MJ, Richens A, Yuen AW. 1995. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345:476-79
63. Frank LM, Enlow T, Holmes GL, et al. 1999. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 40:973-79
64. Janszky J, Rasonyi G, Halasz P, et al. 2000. Disabling erratic myoclonus during lamotrigine therapy with high serum level - report of two cases. Clin. Neuropharmacol. 23:86-89
65. Holmes LB, Wyszynski DF, Baldwin EJ, et al. 2006. Increased risk of nonsyndromic cleft palate amongst infants exposed to lamotrigine during pregnancy. Birth Defect. Res. Part A 76:318
66. Appleton R, Fichtner K, LaMoreaux L, et al. 1999. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 40:1147-54
67. UK Gabapentin Study Group. 1990. Gabapentin in partial epilepsy. Lancet 335:1114-17
68. Anhut H, Ashman P, Feuerstein TJ, et al. 1994. Gabapentin (neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 35:795-801
69. Chadwick DW, Anhut H, Greiner MJ, et al. 1998. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 51:1282-88
70. Asconape J, Diedrich A, DellaBadia J. 2000. Myoclonus associated with the use of gabapentin. Epilepsia 41:479-81
71. Leppik IE, Dreifuss FE, Pledger GW, et al. 1991. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 41:1785-89
72. Faught E, Sachdeo RC, Remler MP, et al. 1993. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 43:688-92
73. Sachdeo R, Kramer LD, Rosenberg A, et al. 1992. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann. Neurol. 32:386-92
74. Devinsky O, Faught RE, Wilder BJ, et al. 1995. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res. 20:241-46
75. The Felbamate Study Group in Lennox-Gastaut Syndrome. 1993. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N. Engl. J. Med. 328:29-33
76. Devinsky O, Kothari M, Rubin R, et al. 1992. Felbamate for absence seizures. Epilepsia 33:84
77. Kuzniecky R, Thompson G, Faught E, et al. 1991. Felbamate add-on therapy in intractable atypical absence. Epilepsia 32:10
78. Carmant L, Holmes GL, Sawyer S, et al. 1994. Efficacy of felbamate in therapy for partial epilepsy in children. J. Pediatr. 125:481-86
79. Leroy RF, Castain T. 1991. Pilot study of felbamate in adult medically refractory primary generalized seizure patients. Epilepsia 32:13
80. Sachdeo RC, Wagner ML. 1991. Felbamate in generalized tonic-clonic seizures. Epilepsia 32:54
81. French J, Smith M, Faught E, et al. 1999. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52:1540-45
82. Pellock JM, Faught E, Leppik IE, et al. 2006. Felbamate: consensus of current clinical experience. Epilepsy Res. 71:89-101
83. Dean C, Mosier M, Penry K. 1999. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40:74-82
84. Bruni J, Guberman A, Vachon L, et al. 2000. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 9:224-32
85. Miller NR, Johnson MA, Paul SR, et al. 1999. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53:2082-87
86. Iannetti P, Spalice A, Perla FM, et al. 2000. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 106:838-42
87. Mackay MT, Weiss SK, Adams-Webber T, et al. 2004. Practice parameter: medical treatment of infantile spasms. Report of the American Academy of Neurology and the Child Neurology Society. Neurology 62:1668-81
88. Bailer M, Johannessen SI, Kupferberg HJ. 2007. Progress report on new antiepileptic drugs: a summary of the eighth Eilat Conference (EILAT VIII). Epilepsy Res. 73:1-52
89. Porter RJ, Partiot A, Sachdeo R, et al. 2007. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68:1197-1204
90. Kwan P, Brodie MJ. 2001. Effectiveness of first antiepileptic drug. Epilepsia 42:1255-60
91. Wiebe S, Blume WT, Girvin JP, et al. 2001. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 345:311-18
92. Engel J Jr., Wiebe S, French J, et al. 2003. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Epilepsia 44:741-51
93. Yasuda CL, Tedeschi H, Oliveira EL, et al. 2006. Comparison of short-term outcome between surgical and clinical treatment in temporal lobe epilepsy: a prospective study. Seizure 15:35-40
94. Fisher RS, Handforth A. 1999. Reassessment: vagus nerve stimulation for epilepsy. A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 53:666-69
95. Morrell M. 2006. Brain stimulation for epilepsy: Can scheduled or responsive neurostimulation stop seizures? Curr. Opin. Neurol. 19:164-68
96. Sinha SR, Kossoff EH. 2005. The ketogenic diet. Neurologist 11:161-70
97. Pfeifer HH, Thiele EA. 2005. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology 65:1810-12
98. Kossoff EH, McGrogan JR, Bluml RM, et al. 2006. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 47:421-24
99. Pavone P, Bianchini R, Trifiletti RR, et al. 2001. Neuropsychological assessment in children with absence epilepsy. Neurology 56:1047-51
100. Motamedi G, Meador K. 2003. Epilepsy and cognition. Epilepsy Behav. 4(Suppl. 2):S25-38
101. Meador KJ. 2002. Cognitive outcomes and predictive factors in epilepsy. Neurology 58:S21-26
102. Gardiner M. 2005. Genetics of idiopathic generalized epilepsies. Epilepsia 46(Suppl. 9)45-20
103. Andermann F, Kobayashi E, Andermann E. 2005. Genetic focal epilepsies: state of the art and paths to the future. Epilepsia 46(Suppl. 10):61-67